Session 3: Vision for Products with Impact and Sustainable Access
|
9:00 – 9:30 a.m.
|
Round Table: PD-1 checkpoint therapies from China: local experience and plans for emerging markets
Moderator: Wenru Song, MD, PhD – Kira Pharma
Panelists: Shirley Zhao – CStone Pharmaceuticals Yong Ben, MD, MBA – BeiGene Sheng Yao, MD – Shanghai Junshi Biosciences Co.
|
9:30 – 9:50 a.m.
|
Barriers and approaches to cancer immunotherapy in LMICs Ute Dugan, MD, PhD – Parker Institute for Cancer Immunotherapy Phangisile Mtshali – Bristol-Myers Squibb Foundation
|
9:50 – 10:10 a.m.
|
Bintrafusp Alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in HPV–associated malignancies Claudia-Nanette Gann, MD – EMD Serono
|
10:10 – 10:30 a.m.
|
Roche perspective on global access to cancer therapies, including I-O Frank Loeffler – Roche Philip Anderson, MD – Roche
|
10:30 – 10:50 a.m.
|
Panel discussion
Moderator: Phangisile Mtshali – Bristol-Myers Squibb Foundation
Panelists: Ute Dugan, MD, PhD – Parker Institute for Cancer Immunotherapy Claudia-Nanette Gann, MD – EMD Serono Frank Loeffler – Roche Philip Anderson, MD – Roche
|
10:50 – 11:00 a.m.
|
Break
|
Session 4: Scientific Questions That Need to be Answered in LMIC’s
|
11:00 – 11:20 a.m.
|
Presentation and survival from breast cancer in SSA Nixon Niyonzima, MD – Uganda Cancer Institute
|
11:20 – 11:40 a.m.
|
Evaluation of immune checkpoint inhibitors in medically vulnerable populations: challenges and opportunities for translational research Elad Sharon, MD, MPH – National Cancer Institute
|
11:40 – 12:00 p.m.
|
Cervical cancer and checkpoint blockade Alfonso Dueñas – Instituto Nacional de Cancerología
|
12:00 - 12:20 p.m. |
Panel discussion
Moderator: Verna Vanderpuye, MD – Bu Teaching Hospital
Panelists: Ramya Ramaswami, MBBS, MPH – National Cancer Institute Elad Sharon, MD, MPH – National Cancer Institute Nixon Niyonzima, MD – Uganda Cancer Institute Alfonso Dueñas – Instituto Nacional de Cancerología Adedayo Joseph, MD – NSIA-LUTH Cancer Center Thomas Uldrick, MD, MS – Fred Hutchinson Cancer Research Center
|
Session 5: Wrap-up: Next Steps and Line of Sight to Recommendations
|
12:20 - 12:40 p.m. |
Accelerating access to cancer immunotherapies: Learning from the global health experience of CHAI, American Cancer Society, and Allied Against Cancer Emily Kobayashi – Clinton Health Access Initiative
|
12:40 - 1:00 p.m |
Round Table: Networking to increase cooperation between regions: Clinical trials, sharing of epidemiologic data, and other areas for collaboration
Moderator: Nora Sobrevilla-Moreno, MD – Instituto Nacional de Cancerología
Panelists: Marisa Nimrod, MD – Caribbean Association of Hematology and Oncology Hanna Simonds, MBChB, MRCP, FRCR – Stellenbosch University Oscar Arrieta, MD, MS – Instituto Nacional de Cancerología Addu Bounedja – Saad Dahlab University
|
1:00 - 1:25 p.m. |
Panel discussion
Moderator: Fredrick Chite Asirwa, MD – International Cancer Institute Eldoret
Panelists: Satish Gopal, MD, MPH – National Cancer Institute David Kaufman, MD, PhD – Third Rock Ventures Samir Khleif, MD – Georgetown University Verna Vanderpuye, MD – Bu Teaching Hospital Nora Sobrevilla-Moreno, MD – Instituto Nacional de Cancerología Tolulope Adewole, MBBS – NSIA-LUTH Cancer Center Zainab Mohamed, MBChB, MMed – University of Cape Town Ute Dugan, MD, PhD – Parker Institute for Cancer Immunotherapy
|
1:25 - 1:30 p.m. |
Conclusion and thank you David Kaufman, MD, PhD – Third Rock Ventures
|